Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. - Wikidata - wikimedia - TriplyDB

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.

http://www.wikidata.org/entity/Q35533363

about

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.

P2860

Q37029841-857BB96F-9C35-4FAF-9DE9-AA1142305C7A

P2860

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.

http://www.wikidata.org/entity/Q35533363

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Prognostic significance of the ...... ced epithelial ovarian cancer.

@ast

Prognostic significance of the ...... ced epithelial ovarian cancer.

@en

type

label

Prognostic significance of the ...... ced epithelial ovarian cancer.

@ast

Prognostic significance of the ...... ced epithelial ovarian cancer.

@en

prefLabel

Prognostic significance of the ...... ced epithelial ovarian cancer.

@ast

Prognostic significance of the ...... ced epithelial ovarian cancer.

@en

P1433

Q35533363-DABAAC41-281F-4B87-993B-8D6D0C38FBE7

P1476

Q35533363-26B44EDC-5F0A-487E-AEE9-C563BE8CD537

P2093

Q35533363-0B872682-13AC-4C0E-88C8-FFE06DB78D1A

Q35533363-2DDF4461-1F5D-4F91-862F-4FA6F32D1276

Q35533363-2E617247-1BD8-494D-A648-889EF8AA76FE

Q35533363-63535F40-1AB6-40D5-8C1E-CE54A0CC763B

Q35533363-6D7BC13A-2AB4-4C97-92FC-5B3DCA98D519

Q35533363-917409B7-C791-4590-B8B5-B0554E827755

Q35533363-A99FDA97-F113-4809-A326-BC46EF310A02

Q35533363-D3FCEA1B-A5A3-438C-8FBC-03B47A841606

Q35533363-FDD18187-BE22-415C-A156-5150BE37539F

P2860

Q35533363-0603CFB8-CE29-495F-B372-91964E6238DB

Q35533363-10F1C8C2-9BA6-4E6B-A79D-DF2E876B819F

Q35533363-16DE387F-5057-4C8B-B08D-899F17222DDC

Q35533363-1A77E761-692E-424B-9EDC-356C9893C1D2

Q35533363-1D42592C-66CC-4075-83F7-8CB52F08CF0F

Q35533363-21BCEA9F-CB88-4A5E-96C4-78281852FB9D

Q35533363-28E457DE-6CCD-4FEC-AA26-9BC5885B5F04

Q35533363-292EC937-D187-497F-AB7A-A2CF380866A0

Q35533363-2FD45385-8531-4775-8C4F-C5626C9F7A9F

Q35533363-562983D0-7E1C-49D4-9F41-AD477EC5A0D7

P304

Q35533363-633AFDD4-24F2-4437-B8C8-6DA4B91C8BC0

P31

Q35533363-8FEBE120-4614-41BC-BC5B-C087DE64149D

P356

Q35533363-7B74DC6F-BA45-4503-A288-CC8CD405D069

P433

Q35533363-75B78AF3-A053-4307-9402-465FC69187C4

P478

Q35533363-04CC77E4-B80F-4380-A4F0-6D85CFB78B6D

P50

Q35533363-375D0B63-ECE9-482F-BBC9-70C1DE687B1D

P577

Q35533363-11FF4890-989D-4AD0-B4F2-9D6E3866F08A

P698

Q35533363-3FDE67CC-2B43-4936-9A15-8A5709490CE0

P932

Q35533363-5577484C-9875-4CE5-9312-ED522C831E06

P356

IGC.0000000000000389

P1433

International Journal of Gynecological Cancer

P1476

Prognostic significance of the ...... nced epithelial ovarian cancer

@en

P2093

Alexia Iasonos

http://www.w3.org/2001/XMLSchema#string

Dennis S Chi

http://www.w3.org/2001/XMLSchema#string

John Denesopolis

http://www.w3.org/2001/XMLSchema#string

Kara C Long Roche

http://www.w3.org/2001/XMLSchema#string

Oliver Zivanovic

http://www.w3.org/2001/XMLSchema#string

Qin Zhou

http://www.w3.org/2001/XMLSchema#string

Richard R Barakat

http://www.w3.org/2001/XMLSchema#string

Roisin E O'Cearbhaill

http://www.w3.org/2001/XMLSchema#string

Rudy S Suidan

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer statistics, 2014

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

A phase 3 trial of bevacizumab in ovarian cancer.

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.

P304

599-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/IGC.0000000000000389

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Edward J Tanner

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25664437

http://www.w3.org/2001/XMLSchema#string

P932

4408230

http://www.w3.org/2001/XMLSchema#string